FDA IS REPORTEDLY EXPECTED TO LIFT RESTRICTION ON PEPTIDES NYT Dihexa for Women: Cognitive and Hormonal Health Benefits BPC 157 FDA Approval Status 2026: RFK Jr, Advisory Committee & Reclassification The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York DIHEXA Research Capsules Peptide Tech